Allarity Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage, precision medicine biopharmaceutical company dedicated to developing personalized cancer treatments. The company's core strategy centers on the clinical development of its lead therapeutic candidate, stenoparib (formerly 2X-121), an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Allarity leverages its proprietary Drug Response Predictor (DRP®) companion diagnostic technology to analyze messenger RNA (mRNA) expression profiles from patient biopsies. This platform is designed to identify patients with gene expression signatures highly likely to respond to specific therapies, thereby refining patient selection, improving clinical outcomes, and reducing clinical trial risk. The company operates as a single operating and reporting segment with principal operations in Denmark and corporate headquarters in Tarpon Springs, Florida.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing clinical development on an amended Phase 2 protocol enrolling only platinum-resistant or platinum-ineligible advanced ovarian cancer patients to accelerate the path toward FDA approval under Fast Track designation.
Expected impact: Optimizes dosing and refines the DRP® companion diagnostic to identify patients most likely to benefit, maximizing clinical efficacy and regulatory success.
Expanding the therapeutic reach of stenoparib by launching a Phase 2 combination trial with temozolomide for relapsed SCLC.
Expected impact: Aims to establish stenoparib as the combination agent of choice in the PARP inhibitor class for difficult-to-treat solid tumors.
Strengthening the proprietary Drug Response Predictor (DRP®) companion diagnostic strategy, supported by a USPTO Notice of Allowance for a patent application covering the stenoparib-specific DRP® test.
Expected impact: Expected to extend the exclusivity period for stenoparib by at least 11 years when used in concert with the DRP® companion diagnostic.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Enables the clinical evaluation of stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC) across 11 VA medical centers.
Terms: Fully funded by the VA's Special Emphasis Panel on Precision Oncology, requiring no direct clinical trial funding from Allarity.
Conducting advanced molecular and cellular studies to clarify the individual and combined contributions of PARP inhibition and WNT pathway modulation to stenoparib's anti-cancer effects.
Terms: Collaborative research agreement with terms not publicly disclosed.